Comparative Pharmacology
Head-to-head clinical analysis: CERETEC versus MPI DTPA KIT CHELATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERETEC versus MPI DTPA KIT CHELATE.
CERETEC vs MPI DTPA KIT - CHELATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m exametazime (Ceretec) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is taken up by brain tissue in proportion to regional cerebral blood flow. Once inside cells, it undergoes intracellular conversion to a hydrophilic form, trapping it in the brain and allowing SPECT imaging.
DTPA (diethylenetriaminepentaacetic acid) chelates paramagnetic metal ions (e.g., gadolinium) to form stable complexes that alter T1 relaxation times during MRI, enhancing contrast.
555-740 MBq (15-20 mCi) intravenously as a single dose for SPECT imaging.
Adult: 3-4 mCi (111-148 MBq) intravenously as a single dose for renal imaging.
None Documented
None Documented
Terminal: 6 hours (range 4–8 h); clinical: supports twice-daily dosing in nuclear medicine studies.
The terminal elimination half-life is approximately 1.7 hours in patients with normal renal function (creatinine clearance >80 mL/min); prolonged to >20 hours in severe renal impairment.
Renal: 40% unchanged; biliary/fecal: 60% (as metabolites and parent compound).
Renal excretion accounts for >95% of the administered dose via glomerular filtration; less than 2% is excreted in feces.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical